Physician profile
Stacey L Johnson
NPI 1154951192
$66,316.39
in general payments reported to CMS, 2019-2025
30 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Community Health (Nurse Practitioner) providers received nationally (typical 2025 total: $139).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,476 · 2022: $6,863 · 2023: $24K · 2024: $16K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Travel and Lodging: $13K · Food and Beverage: $12K · Consulting Fee: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,150 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,950.00 |
| Travel and Lodging | $13,278.56 |
| Food and Beverage | $11,921.00 |
| Consulting Fee | $10,428.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,150.00 |
| Education | $249.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $21,033.25 | 2021-2023 | Krystexxa |
| Abbvie INC. | $18,506.64 | 2021-2025 | |
| Amgen INC. | $8,256.60 | 2021-2025 | Krystexxa, Tavneos, Enbrel |
| Astrazeneca Pharmaceuticals Lp | $3,616.12 | 2022-2025 | Saphnelo, Farxiga |
| Novartis Pharmaceuticals Corporation | $2,646.82 | 2022-2025 | |
| Janssen Biotech, INC. | $2,598.13 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $2,590.56 | 2021-2025 | Orencia, Sotyktu |
| Eli Lilly and Company | $1,200.00 | 2025 | Taltz |
| Intuitive Surgical, INC. | $1,014.31 | 2025 | |
| Mallinckrodt Hospital Products INC. | $992.72 | 2021-2025 | Acthar |
| Glaxosmithkline, LLC. | $614.44 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $569.51 | 2021-2025 | Taltz, Olumiant |
| Pfizer INC. | $390.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.68 | 2024-2025 | Spevigo, Ofev |
| Actelion Pharmaceuticals US, INC. | $299.86 | 2021-2025 | Opsumit, Uptravi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $267.38 | 2023-2025 | Bimzelx, Cimzia |
| Ani Pharmaceuticals, INC. | $193.41 | 2022-2023 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $192.38 | 2022-2023 | Octagam Immune Globulin (Human) |
| Genzyme Corporation | $170.89 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $149.29 | 2024-2025 | Tremfya |
| Kiniksa Pharmaceuticals, Ltd. | $135.00 | 2023 | Arcalyst |
| Alexion Pharmaceuticals, INC. | $112.58 | 2022-2025 | Strensiq, Ultomiris |
| Aurinia Pharma U.S., INC. | $95.54 | 2021-2024 | Lupkynis |
| Fresenius Kabi USA, LLC | $91.01 | 2023-2024 | Idacio |
| Ultragenyx Pharmaceutical INC. | $78.44 | 2021-2024 | Crysvita |
| Sobi, INC | $53.09 | 2021-2024 | |
| Biogen, INC. | $49.52 | 2021 | |
| Genentech USA, INC. | $48.08 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Sandoz INC. | $30.62 | 2025 | Jubbonti |
| Axonics, INC. | $18.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.